Vivos Therapeutics reported Q3 2024 revenue of $3.9 million, up 17% year-over-year, driven by a 34% increase in product revenue to $2.0 million and stable service revenue of $1.9 million. Gross margin improved to 60% from 53% in Q3 2023, while operating loss narrowed to $2.6 million from $3.6 million last year.The company made strategic progress with its new marketing and distribution model, signing a key alliance agreement with Rebis Health Holdings to offer comprehensive sleep apnea treatment solutions. Operating expenses decreased by $0.4 million to $5.0 million, reflecting cost optimization efforts including workforce reductions implemented in 2023 and 2024.As of September 30, 2024, Vivos had $6.3 million in cash following successful capital raises, including a $7.5 million private placement in June and a $4.3 million offering in September. However, management noted additional financing will be needed to fund operations over the next 12 months, as the company works to scale its new strategic alliance model and achieve cash flow positivity.

Vivos Therapeutics reported Q3 2024 revenue of $3.9 million, up 17% year-over-year, driven by a 34% increase in product revenue to $2.0 million and stable service revenue of $1.9 million. Gross margin improved to 60% from 53% in Q3 2023, while operating loss narrowed to $2.6 million from $3.6 million last year.The company made strategic progress with its new marketing and distribution model, signing a key alliance agreement with Rebis Health Holdings to offer comprehensive sleep apnea treatment solutions. Operating expenses decreased by $0.4 million to $5.0 million, reflecting cost optimization efforts including workforce reductions implemented in 2023 and 2024.As of September 30, 2024, Vivos had $6.3 million in cash following successful capital raises, including a $7.5 million private placement in June and a $4.3 million offering in September. However, management noted additional financing will be needed to fund operations over the next 12 months, as the company works to scale its new strategic alliance model and achieve cash flow positivity.